Nobel Lecture: James Allison, Nobel Prize in Physiology or Medicine 2018

Transcript

Read and summarize the transcript of this video on Glasp Reader (beta).

Summary

This video discusses the work of Jim Allison, this year's Nobel laureate in medicine, who has made significant contributions to the field of immunotherapy for cancer treatment. He has been instrumental in the development of immune checkpoint blockade, which has shown promising results in treating various types of cancer. Allison's research has focused on understanding the role of T cells in the immune system and how they can be harnessed to target and eliminate cancer cells. Through his work, he has demonstrated the potential of immunotherapy to revolutionize cancer treatment.

Questions & Answers

Q: What were Jim Allison's early experiences with science?

From a young age, Jim Allison was drawn to science and played with his chemistry set. He was fascinated by dissecting frogs and developed an interest in biology and genetics. He accompanied his father, who was a doctor, on house calls, which led him to realize that he wanted to pursue a career in science rather than follow in his father's footsteps.

Q: How did Jim Allison's experience in high school shape his career path?

In high school, Jim Allison encountered a teacher who refused to teach evolution. Allison, who believed that biology without Darwin was like physics without Newton, refused to take the class. This put him at risk of failing high school. However, a compromise was reached, and he fulfilled the biology requirements by taking college-level biology courses through correspondence with the University of Texas.

Q: What were Jim Allison's groundbreaking discoveries in immunology?

Jim Allison's fundamental discoveries in immunology include defining the structure of the T-cell antigen receptor, demonstrating the co-stimulatory role of cd28 in T-cell activation, and discovering the inhibitory checkpoint molecule ctla4. These discoveries were made through basic research and laid the foundation for the development of immune checkpoint blockade as a potential cancer treatment.

Q: What is immune checkpoint blockade and how does it work?

Immune checkpoint blockade is a strategy that involves blocking the inhibitory signals that prevent T cells from attacking cancer cells. This is achieved by using antibodies to block molecules such as ctla4 and pd1, which are responsible for inhibitory signaling. By blocking these checkpoints, the immune system's response to cancer cells can be enhanced, leading to tumor regression and improved patient outcomes.

Q: What is the significance of immune checkpoint blockade as a cancer treatment strategy?

Immune checkpoint blockade has shown remarkable efficacy in treating various types of cancer, including metastatic melanoma. Prior to the approval of immune checkpoint inhibitors, the prognosis for metastatic melanoma was poor, with a median life expectancy of only 11 months. However, with the introduction of checkpoint inhibitors, patients have achieved durable responses and, in some cases, have experienced long-term remission. This breakthrough treatment approach represents a significant advancement in cancer therapy.

Q: What are the challenges associated with immune checkpoint blockade and cancer treatment?

While immune checkpoint blockade has yielded promising results in many patients, not all patients respond to therapy, and some tumors develop resistance over time. Additionally, immune-related adverse events can occur as a result of treatment, although they are generally manageable. Understanding the mechanisms of resistance and improving patient selection are ongoing challenges in the field of immunotherapy.

Q: How does combination therapy improve the efficacy of immune checkpoint blockade?

Combination therapy involves using multiple checkpoint inhibitors in conjunction with other cancer treatments such as chemotherapy or radiation therapy. This approach has shown improved response rates and overall survival compared to monotherapy. The rationale behind combination therapy is that different checkpoints operate at different stages of T-cell development, allowing for a more comprehensive and durable immune response against the tumor.

Q: What is the immunotherapy platform developed by Jim Allison and his colleagues?

The immunotherapy platform developed by Jim Allison and his colleagues aims to study the cellular mechanisms of immune responses in cancer patients who are being treated with immunotherapy. This platform involves collecting tissue and blood samples from patients and analyzing them using various techniques. The goal is to gain insights into the mechanisms of response and resistance to immunotherapy, as well as to identify potential biomarkers for patient selection and personalized treatment approaches.

Q: What have researchers learned about the cellular mechanisms of response to immune checkpoint blockade?

Through the use of high-dimensional assays such as mass cytometry, researchers have identified distinct subsets of T cells that are associated with response to immune checkpoint blockade. For example, in melanoma patients, CD4+ T cells that express the Icos marker and CD8+ T cells that express high levels of PD1 are both associated with tumor regression. These findings highlight the importance of understanding T cell subsets and their functional characteristics in order to optimize immunotherapy approaches.

Q: What is the potential role of co-stimulation in T cell differentiation and response to immune checkpoint blockade?

Co-stimulation, particularly through the ICOS pathway, appears to play a crucial role in promoting the expansion and activation of tumor-reactive T cells. By removing inhibitory signals and providing co-stimulatory signals, such as ICOS, it is possible to enhance the anti-tumor immune response. Moreover, the absence of co-stimulation can influence the differentiation of T cells towards different functional subsets. Understanding the intricate interplay between co-stimulation and inhibition could pave the way for the development of more effective immunotherapies.

Takeaways

Jim Allison's groundbreaking work in immune checkpoint blockade has revolutionized cancer treatment. Through his research, he has shown that targeting the immune system rather than the tumor itself can lead to durable responses and even complete remission in patients with metastatic melanoma. Immune checkpoint inhibitors, such as antibodies targeting ctla4 and pd1, have received approval for the treatment of various types of cancer and have demonstrated remarkable efficacy in clinical trials. Combination therapy, which involves multiple checkpoint inhibitors and other treatments, has further improved response rates and overall survival. The development of an immunotherapy platform has allowed for a deeper understanding of the cellular mechanisms underlying immune responses and resistance to therapy. By studying the different subsets of T cells and their functional characteristics, researchers can identify potential biomarkers and develop personalized treatment approaches. Co-stimulation, particularly through the ICOS pathway, has emerged as a key factor in T cell differentiation and response to immunotherapy. Further research in this field holds great promise for improving cancer treatment outcomes.